论文部分内容阅读
目的观察达美康缓释片与甘精胰岛素联合治疗II型糖尿病疗效及其对血脂的影响。方法选择2008年7月—2010年6月在门诊或住院诊治的II型糖尿病患者130例,随机将其分为观察组和对照组各65例。对照组予以清晨口服甘精胰岛素,并睡前注射中性鱼精蛋白锌胰岛素;观察组给予清晨口服甘精胰岛素,并于早餐前30min服用达美康缓释片,1次/d;2组患者疗程均为8周。结果 2组治疗后FBG、2hBG和HbA1c与治疗前比较均明显下降(P<0.01),治疗后2组FBG、2hBG和HbA1c比较差异无统计学意义(>0.05)。2组低血糖事件发生率比较,观察组9.23%(6/65),对照组33.85%(22/65),2组比较差异有统计学意义(P<0.01);2组治疗8周前后血清CP水平改变情况:对照组治疗前后空腹和餐后CP无明显改善,而观察组治疗后空腹和餐后CP水平均明显升高。结论甘精胰岛素联合达美康缓释片治疗II型糖尿病疗效确定,具有良好的安全性,能够大大减少低血糖的风险,并能较好控制空腹血糖和餐后血糖。
Objective To observe the curative effect and the effect on the blood lipids of type 2 diabetes mellitus treated with the combination of DaMeiKang sustained release tablets and insulin glargine. Methods 130 patients with type 2 diabetes who were diagnosed and treated in clinic or in hospital from July 2008 to June 2010 were randomly divided into observation group (65 cases) and control group (65 cases). In the control group, glargine was given orally in the morning and injected with neutral protamine zinc insulin before going to bed. The observation group was given oral glargine at an early morning and was given a daclime sustained-release tablet 30 min before breakfast. The rats in the two groups Patients were treated for 8 weeks. Results After treatment, FBG, 2hBG and HbA1c in two groups were significantly decreased compared with those before treatment (P <0.01). There was no significant difference in FBG, 2hBG and HbA1c between the two groups after treatment (P> 0.05). The incidence of hypoglycaemia in the two groups was significantly higher than that in the control group (9.23% (6/65) in the observation group and 33.85% (22/65) in the control group) (P <0.01) CP level changes: the control group before and after fasting and postprandial CP no significant improvement, while the observation group after treatment fasting and postprandial CP levels were significantly higher. Conclusion The combination of glargine and meticolon sustained-release tablets in the treatment of type 2 diabetes has good curative effect, which can reduce the risk of hypoglycemia and control fasting blood glucose and postprandial blood glucose.